Burgos-Alonso et al.(1414 Burgos-Alonso N, Lobato I, Hernandez I, Sebastian KS, Rodriguez B, March AG, et al. Autologous platelet-rich plasma in the treatment of venous leg ulcers in primary care: a randomised controlled, pilot study. J Wound Care. 2018;27(Sup6):S20-S4. doi: 10.12968/jowc.2018.27.Sup6.S20 https://doi.org/10.12968/jowc.2018.27.Su...
) 2018 Espanha |
Estudo piloto de Ensaio Clínico Randomizado com análise de custo-minimização Tempo de seguimento (TS) = 9 semanas |
Gel de Plasma Rico em Plaquetas (n = 7) versus Tratamento padrão (n = 5) |
1b/A |
Moneibet al.(1515 Moneib HA, Youssef SS, Aly DG, Rizk MA, Abdelhakeem YI. Autologous platelet-rich plasma versus conventional therapy for the treatment of chronic venous leg ulcers: A comparative study. J Cosmet Dermatol. 2018;17(3):495-501. doi: 10.1111/jocd.12401 https://doi.org/10.1111/jocd.12401...
) 2018 Egito |
Caso-controle TS = 6 semanas |
Plasma Rico em Plaquetas (n = 20) versus Tratamento convencional com gaze vaselinada e salina (n = 20) |
3b/B |
Cardeñosaet al.(1616 Cardeñosa ME, Dominguez-Maldonado G, Cordoba-Fernandez A. Efficacy and safety of the use of platelet-rich plasma to manage venous ulcers. J Tissue Viability. 2017;26(2):138-43. doi: 10.1016/j.jtv.2016.11.003 https://doi.org/10.1016/j.jtv.2016.11.00...
) 2017 Espanha |
Ensaio Clínico Randomizado TS = 24 semanas |
Gel de plaquetas ricas em fatores de crescimento (n = 55) versus Solução salina (n = 47) |
1b/A |
Somani&Rai(1717 Somani A, Rai R. Comparison of efficacy of Autologous Platelet-rich Fibrin versus Saline Dressing in Chronic Venous Leg Ulcers: a randomised controlled trial. J Cutan Aesthet Surg. 2017;10(1):8-12. doi: 10.4103/JCAS.JCAS_137_16 https://doi.org/10.4103/JCAS.JCAS_137_16...
) 2017 Índia |
Ensaio Clínico Randomizado TS = 4 semanas |
Fibrina rica em plaquetas (n = 9) versus Solução salina (n = 6) |
1b/A |
Senetet al.(1818 Senet P, Bon FX, Benbunan M, Bussel A, Traineau R, Calvo F, et al. Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers. J Vasc Surg. 2003;38(6):1342-8. doi: 10.1016/S0741 https://doi.org/10.1016/S0741...
) 2003 França |
Ensaio Clínico Randomizado Duplo cego TS = 12 semanas |
Plaquetas autólogas congeladas (n = 8) versus Hidrocolóide (n = 7) |
1b/A |
Stacey et al.(1919 Stacey MC, Mata SD, Trengove NJ, Mather CA. Randomised double-blind placebo-controlled trial of topical autologous platelet lysate in venous ulcer healing. Eur J Vasc Endovasc Surg;20(3):296-301. doi: 10.1053/ejvs.2000.1134 https://doi.org/10.1053/ejvs.2000.1134...
) 2000 Austrália |
Ensaio Clínico Randomizado Duplo cego TS = 9 meses |
Plaquetas lisadas (n = 42) versus Placebo (n = 44) |
|
Pinto et al.(2020 Pinto NR, Ubilla M, Zamora Y, Del Rio V, Dohan Ehrenfest DM, Quirynen M. Leucocyte- and platelet-rich fibrin (L-PRF) as a regenerative medicine strategy for the treatment of refractory leg ulcers: a prospective cohort study. Platelets. 2018;29(5):468-75. doi: 10.1080/09537104.2017.1327654 https://doi.org/10.1080/09537104.2017.13...
) 2018 Chile |
Coorte prospectiva TS = 1 ano |
Membrana de Fibrina rica em leucócito e plaqueta (L-PRF) (n = 32) |
2b/B |
Waniczeket al.(2121 Waniczek D, Mikusek W, Kaminski T, Wesecki M, Lorenc Z, Cieslik-Bielecka A. The "biological chamber" method - use of autologous platelet-rich plasma (PRP) in the treatment of poorly healing lower-leg ulcers of venous origin. Pol Przegl Chir. 2015;87(6):283-9. doi: 10.1515/pjs-2015-0055. https://doi.org/10.1515/pjs-2015-0055...
) 2015 Polônia |
Série de casos TS = 10 semanas |
Plasma Rico em Plaquetas (n = 10) |
4/C |
Kim et al.(2222 Kim SA, Ryu HW, Lee KS, Cho JW. Application of platelet-rich plasma accelerates the wound healing process in acute and chronic ulcers through rapid migration and upregulation of cyclin A and CDK4 in HaCaT cells. Mol Med Rep. 2013;7(2):476-80. doi: 10.3892/mmr.2012.1230 https://doi.org/10.3892/mmr.2012.1230...
) 2013 República da Coréia |
Série de casos TS = Não informa |
Gel de plaquetas autólogo ou líquido (n = 3) |
4/C |
Park et al.(2323 Park KY, Kim IS, Yeo IK, Kim BJ, Kim MN. Treatment of refractory venous stasis ulcers with autologous platelet-rich plasma and light-emitting diodes: a pilot study. J Dermatolog Treat. 2013;24(5):332-5. doi: 10.3109/09546634.2012.735637 https://doi.org/10.3109/09546634.2012.73...
) 2013 Coréia do Sul |
Estudo piloto TS = 6 semanas |
Gel de Plasma Rico em Plaquetas (n= 16) |
4/C |
Sarvajnamurphyet al.(77 Sarvajnamurthy S, Suryanarayan S, Budamakuntala L, Suresh DH. Autologous platelet rich plasma in chronic venous ulcers: study of 17 cases. J Cutan Aesthet Surg.2013;6(2):97-9. doi: 10.4103/0974-2077.112671 https://doi.org/10.4103/0974-2077.112671...
) 2013 Índia |
Série de casos TS = 6 semanas |
Gel de plaquetas (n = 17) |
4/C |
Leon et al.(2424 Leon JM, Driver VR, Fylling CP, Carter MJ, Anderson C, Wilson J, et al. The clinical relevance of treating chronic wounds with an enhanced near-physiological concentration of platelet-rich plasma gel. Adv Skin Wound Care. 2011;24(8):357-68. doi: 10.1097/01.ASW.0000403249.85131.6f https://doi.org/10.1097/01.ASW.000040324...
) 2011 EUA |
Estudo observacional de banco de dados de 39 centros TS = 2,1 semanas |
Gel de Plasma Rico em Plaquetas (Autologel™) (n = 32) |
4/C |
Frykberget al.(2525 Frykberg RG, Driver VR, Carman D, Lucero B, Borris-Hale C, Fylling CP, et al. Chronic wounds treated with a physiologically relevant concentration of platelet-rich plasma gel: a prospective case series. Ostomy Wound Manage [Internet]. 2010 [cited 2018 Aug 08];56(6):36-44. Available from: https://www.o-wm.com/content/chronic-wounds-treated-physiologically-relevant-concentration-platelet-rich-plasma-gel-prosp. https://www.o-wm.com/content/chronic-wou...
) 2010 EUA |
Série de casos TS = 2,8 semanas |
Gel de Plasma Rico em Plaquetas (Autologel™) (n = 16) |
4/C |
O'Connellet al.(2626 O'Connell SM, Impeduglia T, Hessler K, Wang XJ, Carroll RJ, Dardik H. Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. Wound Repair Regen. 2008;16(6):749-56. doi: 10.1111/j.1524-475X.2008.00426.x https://doi.org/10.1111/j.1524-475X.2008...
) 2008 EUA |
Estudo piloto TS = 16 semanas |
Membrana de fibrina rica em plaquetas (MFRP)/ 1 a 3 aplicações/ (n = 17) Tam. 11,2 (0,7-58) |
4/C |
Gürgen, M(2727 Gürgen M. Treatment of chronic wounds with autologous platelet-rich plasma. EWMA Journal [Internet]. 2008 [cited 2018 Aug 08];8(2):5-10. Available from: https://pdfs.semanticscholar.org/b559/e80bee2ad1591847cb514c741a4fee2befa5.pdf
https://pdfs.semanticscholar.org/b559/e8...
) 2008 Noruega |
Estudo prospectivo TS = 10 meses |
Plasma Rico em Plaquetas (n = 7) |
4/C |